

Mariele Gatto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9101907/mariele-gatto-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84
papers

4,767
citations

28
h-index

68
g-index

101
ext. papers

5,748
ext. citations

8.8
avg, IF

5.9
L-index

#	Paper	IF	Citations
84	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management.. <i>Clinical Reviews in Allergy and Immunology</i> , 2022 , 1	12.3	1
83	Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Analysis of Three Phase III Clinical Trials of Belimumab.. <i>Frontiers in Immunology</i> , 2022 , 13, 796508	8.4	1
82	Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.. <i>Frontiers in Medicine</i> , 2022 , 9, 852162	4.9	0
81	The Influence of Dietary Intervention in Connective Tissue Diseases: Evidence from Randomized Clinical Trials 2021 , 1, 5-16		0
80	Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis.. <i>Autoimmunity Reviews</i> , 2021 , 21, 103018	13.6	0
79	Belimumab: a step forward in the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 563-573	5.4	4
78	Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. <i>Rheumatology</i> , 2021 ,	3.9	1
77	Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. <i>Journal of Nephrology</i> , 2021 , 34, 389-398	4.8	6
76	Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion. <i>Rheumatology</i> , 2021 , 60, 1313-1320	3.9	5
75	Lymphocyte immunophenotyping in inflammatory myositis: a review. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 522-528	5.3	3
74	IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2021 , 124, 102725	15.5	0
73	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021 , 124, 102729	15.5	3
72	Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211040696 ²	3.8	2
71	Deletions in are a risk factor for antibody-mediated kidney disease.. <i>Cell Reports Medicine</i> , 2021 , 2, 100475	15	1
70	Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1077-1083	2.4	13
69	SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. <i>Journal of Autoimmunity</i> , 2020 , 112, 102502	15.5	59
68	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1314-1324	9.5	24

67	Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: Insights from renal ultrastructural findings. <i>Journal of Autoimmunity</i> , 2020 , 111, 102443	15.5	2
66	Physicians' global assessment is often useful in SLE, but not always: the case of clinical remission. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
65	Nonimmune mechanisms in idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 515-522	5.3	4
64	Lupus nephritis: clinical presentations and outcomes in the 21st century. <i>Rheumatology</i> , 2020 , 59, v39-v51	5.9	24
63	Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. <i>Rheumatology</i> , 2020 , 59, 1591-1598	3.9	18
62	Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 943-950	2.4	13
61	Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 124, 188-194	2.2	
60	Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 754-759	2.2	26
59	IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. <i>Experimental Biology and Medicine</i> , 2019 , 244, 42-51	3.7	28
58	Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2019 , 10, 29	8.4	8
57	Preclinical and early systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019 , 33, 101422	5.3	9
56	Pulmonary involvement in antisynthetase syndrome. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 603-610	5.3	13
55	New therapeutic strategies in systemic lupus erythematosus management. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 30-48	8.1	58
54	Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 54, 331-343	12.3	23
53	Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1318-1325	2.4	63
52	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. <i>Journal of Autoimmunity</i> , 2018 , 86, 1-8	15.5	57
51	Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 104-110	2.4	77
50	Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. <i>Autoimmunity Reviews</i> , 2018 , 17, 11-18	13.6	14

49	Diagnostic and prognostic role of renal histopathology in rheumatic diseases. <i>Reumatismo</i> , 2018 , 70, 165-177	1.1	
48	SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype. <i>Frontiers in Immunology</i> , 2018 , 9, 2081	8.4	3
47	Cardiac Involvement in Systemic Lupus Erythematosus. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 265-293	0.3	
46	The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 562-565	2.4	54
45	The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty?. <i>Autoimmunity Reviews</i> , 2017 , 16, 1119-1124	13.6	8
44	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The consensus and the clinical grey zone in autoimmune disease management.	13.6	84
43	How I treat idiopathic patients with inflammatory myopathies in the clinical practice. <i>Autoimmunity Reviews</i> , 2017 , 16, 999-1007	13.6	17
42	Role of galectin-3 in autoimmune and non-autoimmune nephropathies. <i>Autoimmunity Reviews</i> , 2017 , 16, 34-47	13.6	27
41	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017 , 69, 115-123	4.7	74
40	Autoantibody testing in patients with myositis: clinical accuracy of a multiparametric line immunoassay. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 176-177	2.2	13
39	The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission. <i>Israel Medical Association Journal</i> , 2017 , 19, 454-458	0.9	2
38	Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review. <i>Journal of Autoimmunity</i> , 2016 , 69, 1-11	15.5	28
37	Advances in the diagnosis and classification of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 1309-1320	5.1	24
36	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016 , 74, 194-200	15.5	55
35	Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. <i>Journal of Autoimmunity</i> , 2016 , 74, 94-105	15.5	30
34	Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. <i>Journal of Autoimmunity</i> , 2016 , 74, 208-216	15.5	20
33	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016 , 74, 6-12	15.5	69
32	17- β estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice. <i>Lupus</i> , 2015 , 24, 382-91	2.6	12

31	Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2117-22	2.4	121
30	Galectin-3 in autoimmunity and autoimmune diseases. <i>Experimental Biology and Medicine</i> , 2015 , 240, 1019-28	3.7	79
29	Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. <i>Lupus</i> , 2015 , 24, 507-15	2.6	20
28	PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015 , 49, 217-26	12.3	26
27	Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1373-85	4.1	15
26	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2015 , 34, 1571-80	3.9	25
25	Rheumatic and autoimmune thyroid disorders: a causal or casual relationship?. <i>Autoimmunity Reviews</i> , 2015 , 14, 57-63	13.6	14
24	Experimental Models of Adjuvants 2015 , 35-42		
23	Infections and Idiopathic Inflammatory Myopathies 2015 , 715-727		
22	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 449-56	2.2	51
21	Optimizing outcome in SLE: treating-to-target and definition of treatment goals. <i>Autoimmunity Reviews</i> , 2014 , 13, 770-7	13.6	77
20	The clinical features, diagnosis and classification of dermatomyositis. <i>Journal of Autoimmunity</i> , 2014 , 48-49, 122-7	15.5	106
19	In-/off-label use of biologic therapy in systemic lupus erythematosus. <i>BMC Medicine</i> , 2014 , 12, 30	11.4	17
18	Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , 2014 , 5, 95-100	3.7	5
17	Predictors of maternal and fetal complications in SLE patients: a prospective study. <i>Immunologic Research</i> , 2014 , 60, 170-6	4.3	65
16	The olfactory function is impaired in patients with idiopathic inflammatory myopathies. <i>Immunologic Research</i> , 2014 , 60, 247-52	4.3	5
15	A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab--comments on article by Fredericks et al. <i>Lupus</i> , 2014 , 23, 1445-6	2.6	1
14	Serpins, immunity and autoimmunity: old molecules, new functions. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 45, 267-80	12.3	63

13	Premature coronary heart disease in SLE: can we prevent progression?. <i>Lupus</i> , 2013 , 22, 1232-42	2.6	26
12	Emerging and critical issues in the pathogenesis of lupus. <i>Autoimmunity Reviews</i> , 2013 , 12, 523-36	13.6	96
11	Autophagy in human health and disease. <i>New England Journal of Medicine</i> , 2013 , 368, 651-62	59.2	1736
10	Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 45, 227-35	12.3	23
9	Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. <i>Immunologic Research</i> , 2013 , 56, 362-70	4.3	35
8	Overlap connective tissue disease syndromes. <i>Autoimmunity Reviews</i> , 2013 , 12, 363-73	13.6	113
7	Autophagy in human health and disease. <i>New England Journal of Medicine</i> , 2013 , 368, 1845-6	59.2	545
6	Human papillomavirus vaccine and systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2013 , 32, 1301-7	3.7	84
5	Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. <i>PLoS ONE</i> , 2013 , 8, e71458	3.7	62
4	Pregnancy and vasculitis: a systematic review of the literature. <i>Autoimmunity Reviews</i> , 2012 , 11, A447-59	13.6	58
3	Autoinflammation and autoimmunity: bridging the divide. <i>Autoimmunity Reviews</i> , 2012 , 12, 22-30	13.6	139
2	Vaccination of mice for research purpose: alum is as effective as and safer than complete Freund adjuvant. <i>Reumatismo</i> , 2012 , 64, 380-7	1.1	8
1	Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, 856-63	2.2	51